{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:01:54Z","timestamp":1790006514272,"version":"4.0.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study explores the incidence of patient-reported major toxicity\u2014symptoms rated \u201cmoderate,\u201d \u201csevere,\u201d or \u201cvery severe\u201d\u2014for chemotherapy regimens commonly used in early breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Female patients aged 21 years or older completed a validated Patient-Reported Symptom Monitoring instrument and rated 17 symptoms throughout adjuvant or neoadjuvant chemotherapy. Fisher's exact tests compared differences in percentages in symptom ratings, and general linear regression was used to model the incidence of patient-reported major toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 152 patients, the mean age was 54 years (range, 24\u201377), and 112 (74%) were white; 51% received an anthracycline-based regimen. The proportion of patients rating fatigue, constipation, myalgia, diarrhea, nausea, peripheral neuropathy, and swelling of arms or legs as a major toxicity at any time during chemotherapy varied significantly among four chemotherapy regimens (p &amp;lt; .05). The mean (SD) number of symptoms rated major toxicities was 6.3 (3.6) for anthracycline-based and 4.4 (3.5) for non-anthracycline-based regimens (p = .001; possible range, 0\u201317 symptoms). Baseline higher body mass index (p = .03), patient-reported Karnofsky performance status \u226480 (p = .0003), and anthracycline-based regimens (p = .0003) were associated with greater total number of symptoms rated major toxicities (alternative model: chemotherapy duration, p &amp;lt; .0001). Twenty-six percent of dose reductions (26 of 40), 75% of hospitalizations (15 of 20), and 94% of treatment discontinuations (15 of 16) were in anthracycline-based regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Capturing multiple toxicity outcomes throughout chemotherapy enables oncologists and patients to understand the range of side effects as they discuss treatment efficacies. Continuous symptom monitoring may aid in the timely development of interventions that minimize toxicity and improve outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0590","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T20:16:41Z","timestamp":1544818601000},"page":"762-771","source":"Crossref","is-referenced-by-count":84,"title":["Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Kirsten A.","family":"Nyrop","sequence":"first","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Deal","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit S.","family":"Shachar","sequence":"additional","affiliation":[{"name":"Rambam Health Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce B.","family":"Reeve","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul Ki","family":"Choi","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan T.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey K.","family":"Anders","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Dees","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Jolly","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Reeder-Hayes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen G.","family":"Kimmick","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan S.","family":"Karuturi","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, University of Texas, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel E.","family":"Reinbolt","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllen C.","family":"Speca","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyman B.","family":"Muss","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"2021122507020801200_R1","author":"Cancer Stat Facts: Female Breast Cancer"},{"key":"2021122507020801200_R2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3322\/caac.21412","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"suppl 1","key":"2021122507020801200_R3","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3747\/co.22.2321","article-title":"Adjuvant chemotherapy for early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline","volume":"22","author":"Gandhi","year":"2015","journal-title":"Curr Oncol"},{"key":"2021122507020801200_R4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","article-title":"Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Gradishar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122507020801200_R5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group E (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"2021122507020801200_R6","author":"National Cancer Institute"},{"key":"2021122507020801200_R7","first-page":"15","article-title":"Assessment of toxicity in cooperative oncology clinical trials: The long and short of it","volume":"11","author":"Gwede","year":"2002","journal-title":"J Oncol Manag"},{"key":"2021122507020801200_R8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122507020801200_R9","first-page":"139","article-title":"Capturing the patient perspective: Patient-reported outcomes as clinical trial endpoints","volume-title":"Am Soc Clin Oncol Educ Book","author":"Bruner","year":"2012"},{"issue":"9","key":"2021122507020801200_R10","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122507020801200_R11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1740774517698645","article-title":"Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE","volume":"14","author":"Mendoza","year":"2017","journal-title":"Clin Trials"},{"key":"2021122507020801200_R12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11136-013-0470-1","article-title":"Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"23","author":"Hay","year":"2014","journal-title":"Qual Life Res"},{"key":"2021122507020801200_R13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021122507020801200_R14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/PPO.0b013e31822c28b3","article-title":"Electronic toxicity monitoring and patient-reported outcomes","volume":"17","author":"Basch","year":"2011","journal-title":"Cancer J"},{"key":"2021122507020801200_R15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122507020801200_R16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijrobp.2017.02.002","article-title":"Feasibility of patient reporting of symptomatic adverse events via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a chemoradiotherapy cooperative group multicenter clinical trial","volume":"98","author":"Basch","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122507020801200_R17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinthera.2016.03.011","article-title":"Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials","volume":"38","author":"Basch","year":"2016","journal-title":"Clin Ther"},{"key":"2021122507020801200_R18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12955-016-0426-6","article-title":"Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"14","author":"Bennett","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"2021122507020801200_R19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122507020801200_R20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2016.08.335","article-title":"Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life","volume":"143","author":"Cowan","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122507020801200_R21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41687-017-0005-6","article-title":"Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients","volume":"1","author":"Baeksted","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2021122507020801200_R22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1740774515615540","article-title":"Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial","volume":"13","author":"Basch","year":"2016","journal-title":"Clin Trials"},{"key":"2021122507020801200_R23","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2012.47.6804","article-title":"Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy","volume":"31","author":"Judson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JOP.2016.015610","article-title":"Implementation of symptom questionnaires into oncology workflow","volume":"12","author":"Stover","year":"2016","journal-title":"J Oncol Pract"},{"key":"2021122507020801200_R25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jamia\/ocu007","article-title":"Incorporating the patient's voice into electronic health records through patient-reported outcomes as the \u201creview of systems.\u201d","volume":"22","author":"Chung","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"2021122507020801200_R26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.4719","article-title":"Missing patients\u2019 symptoms in cancer care delivery--The importance of patient-reported outcomes","volume":"2","author":"Basch","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122507020801200_R27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","article-title":"New frontiers in patient-reported outcomes: Adverse event reporting, comparative effectiveness, and quality assessment","volume":"65","author":"Basch","year":"2014","journal-title":"Annu Rev Med"},{"key":"2021122507020801200_R28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.adro.2016.02.001","article-title":"Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study","volume":"1","author":"Falchook","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"2021122507020801200_R30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamaoncol.2015.4720","article-title":"Self-evaluation of adjuvant chemotherapy-related adverse effects by patients with breast cancer","volume":"2","author":"Montemurro","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122507020801200_R31","doi-asserted-by":"crossref","first-page":"dju129","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122507020801200_R32","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2017.10.024","article-title":"What do \u201cnone,\u201d \u201cmild,\u201d \u201cmoderate,\u201d \u201csevere,\u201d and \u201cvery severe\u201d mean to patients with cancer? Content validity of PRO-CTCAE response scales","volume":"55","author":"Atkinson","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"2021122507020801200_R33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R34","volume-title":"AJCC Cancer Staging Manual","author":"American Joint Commission on Cancer","year":"2010","edition":"7th ed"},{"key":"2021122507020801200_R35","doi-asserted-by":"crossref","first-page":"djx162","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2021122507020801200_R36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/0284186X.2014.969846","article-title":"Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer","volume":"54","author":"Eckhoff","year":"2015","journal-title":"Acta Oncol"},{"key":"2021122507020801200_R37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-017-4437-8","article-title":"Long-term peripheral neuropathy symptoms in breast cancer survivors","volume":"166","author":"Mustafa Ali","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507020801200_R38","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00520-017-3631-x","article-title":"Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer","volume":"25","author":"Song","year":"2017","journal-title":"Support Care Cancer"},{"key":"2021122507020801200_R39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507020801200_R40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00520-012-1688-0","article-title":"A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment","volume":"21","author":"Reilly","year":"2013","journal-title":"Support Care Cancer"},{"key":"2021122507020801200_R41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/epirev\/mxx008","article-title":"Patient-reported physical function measures in cancer clinical trials","volume":"39","author":"Atkinson","year":"2017","journal-title":"Epidemiol Rev"},{"key":"2021122507020801200_R42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejon.2008.01.005","article-title":"Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women","volume":"12","author":"Browall","year":"2008","journal-title":"Eur J Oncol Nurs"},{"key":"2021122507020801200_R43","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2014.06.007","article-title":"Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK\/01\/001)","volume":"50","author":"Hall","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122507020801200_R44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122507020801200_R45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0885-3924(99)00082-2","article-title":"Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates","volume":"18","author":"Jacobsen","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"2021122507020801200_R46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/annonc\/mdh229","article-title":"Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy","volume":"15","author":"Jong","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122507020801200_R47","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00520-015-2616-x","article-title":"Identification of distinct fatigue trajectories in patients with breast cancer undergoing adjuvant chemotherapy","volume":"23","author":"Junghaenel","year":"2015","journal-title":"Support Care Cancer"},{"key":"2021122507020801200_R48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jpainsymman.2013.05.010","article-title":"Prospective longitudinal evaluation of a symptom cluster in breast cancer","volume":"47","author":"Sanford","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122507020801200_R49","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2005.04.275","article-title":"Patient online self-reporting of toxicity symptoms during chemotherapy","volume":"23","author":"Basch","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1197\/jamia.M2177","article-title":"Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities","volume":"14","author":"Basch","year":"2007","journal-title":"J Am Med Inform Assoc"},{"key":"2021122507020801200_R51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2021122507020801200_R52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-016-3855-3","article-title":"A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: The breast cancer quality of care study (BQUAL)","volume":"158","author":"Neugut","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507020801200_R53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1634\/theoncologist.2017-0672","article-title":"Adjuvant anthracyclines in breast cancer: What is their role?","volume":"23","author":"Shah","year":"2018","journal-title":"The Oncologist"},{"key":"2021122507020801200_R54","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2013.49.3676","article-title":"Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer","volume":"32","author":"Barcenas","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R55","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","article-title":"Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience","volume":"25","author":"Muss","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507020801200_R56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5306\/wjco.v5.i3.529","article-title":"Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines","volume":"5","author":"Crozier","year":"2014","journal-title":"World J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/762\/41917299\/oncolo_24_6_762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/762\/41917299\/oncolo_24_6_762.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:03:25Z","timestamp":1640415805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/762\/6439278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0590","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2018,12,14]]}}}